Daniel Baldoni, MD - Founder and Owner
Daniel has spent his career at the forefront of the emerging neuromodulation industry. Following medical school, he worked in the Advanced Technology team at Nevro where his job was to come up with neuromodulation commercial innovations to feed Nevro’s product pipeline. After leading clinical and regulatory efforts for both deep brain and spinal cord stimulation, Daniel focused his efforts toward noninvasive device development to help patients with aggressive cancer. His combination high-frequency electrical current and ultrasound hyperthermia treatment for glioblastoma will help drive forward the expanding and profitable neuromodulation oncology market. He also has experience in consumer health and currently offers several profitable products including a gyroscopic tremor device.
Yusuf Tufail, PhD - Technology
Yusuf is a Senior Research Scientist at the Lundbeck La Jolla Research Center and formerly Project Scientist at the Salk Institute in La Jolla, CA. He has an extensive background in ultrasonic neuromodulation and ultrasonic technology development. He is a highly motivated and team-oriented neuroscientist with a background in neuro-glia biology and experience with discovering novel proof-of-concept therapies for synaptic, neuroinflammatory and neurodegenerative diseases. He is dedicated to hypothesis driven research projects aimed at discovering therapies to correct dysfunctions of the Central Nervous System. He has been discussing the proposed project for some time with Daniel and looks forward to continue contributing to move this development forward. His expertise in ultrasound design and engineering will be integral in preclinical and clinical application.
John Baldoni, PhD - Executive Advisor
|John has 41 years of experience in the pharmaceutical industry with 29 years at GlaxoSmithKline (GSK) in Research and Development and 11 years on its Executive Leadership Team. He continues to serve on non-Executive Boards, Scientific Advisory Boards and consultantships for several healthcare companies. He has participated in the research and development of more than 50 commercial products and is a proponent of seeking, integrating, and implementing innovative approaches to therapeutic discovery and development. He led several GSK platform innovation initiatives through internal teams, and technology acquisition and partnerships. He conceptualized and was senior science advisor of the Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium, an open membership, public/private partnership currently comprised of GSK, Lawrence Livermore National Laboratory, Frederick National Laboratory for Cancer Research, and the University of California, San Francisco. He was the former Chair of the Executive Committee of the Alliance for Artificial Intelligence in Healthcare, an organization formed to foster improved healthcare by responsible investment, invention and innovation in artificial intelligence.|